profit from every ₹100 of sales.
₹0₹100
Corona Remedies
₹2,320.60-0.99% today
+61.5% in 1 year
1-year low ₹1,347.251-year high ₹2,540.65
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹76.67 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Corona Remedies sold, what it kept, and what it did with the cash.
Sales went from ₹8.84 billion in 2023 to ₹14.0 billion in 2026, with ₹1.85 billion of profit last year.
SalesProfit
Corona Remedies handed back 81% of the cash it generated last year.
₹447M
Free cash flow 2026₹553M
Bought back its own shares–
Paid as dividends₹447M
Cash vs. debt₹18M vs. ₹1.6B
Corona Remedies vs. similar companies
Corona Remedies grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Corona Remedies | 76.7× · Very expensive | ||
 Eli Lilly | 62.3× · Very expensive | ||
 Johnson & Johnson | 25.7× · Fair price | ||
 AbbVie | 123.4× · Very expensive | ||
 Roche | 25.5× · Fair price |
AI analysis
An AI analyst reads Corona Remedies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 8,835 | 10,137 | 11,964 | 14,032 | |
| 6,726 | 7,869 | 9,599 | 11,422 | |
| 1,081 | 1,278 | 2,028 | 2,556 | |
| 1,334 | 1,583 | 2,463 | 2,853 | |
| 849 | 905 | 1,494 | 1,851 | |
| 13.89 | 14.80 | 24.43 | – | |
| 76.1% | 77.6% | 80.2% | 81.4% | |
| 12.2% | 12.6% | 17.0% | 18.2% | |
| 9.6% | 8.9% | 12.5% | 13.2% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 5,950 | 8,306 | 9,299 | 12,051 |
| Cash | 145 | 32 | 32 | 18 |
| Total debt | 280 | 1,590 | 862 | 1,649 |
| Total liabilities | 1,865 | 3,502 | 3,235 | 4,583 |
| 4,085 | 4,804 | 6,063 | 7,469 | |
| 61 | 61 | 61 | – | |
| 20.5% | 16.1% | 23.9% | 21.4% | |
| 20.8% | 18.8% | 24.6% | 24.8% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 1,027 | 1,568 | 1,905 | 2,295 | |
| 948 | 2,863 | 917 | 1,741 | |
| 79 | -1,296 | 988 | 553 | |
| Dividends paid | 70 | 169 | 226 | 447 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 76.7×
- –
- –
- 13.8×
- 10.1×
- 256.5×
- 50.3×
- 0.4%
- 1.3%
- 0.3%
Profitability
- 81.4%
- 18.2%
- 13.2%
- –
- 20.4%
- 19.4%
- –
- –
- –
- –
Growth
- +16.7%
- –
- –
- –
- +0.0%
Financial health
- 0.6×
- 0.22
- –
- 35.5×
- 0.96
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 8%of 946
Top 27%of 871
Bottom 13%of 563
Top 34%of 867
Bottom 43%of 986
0.3%of the share price, paid each year
On $1,000 invested$3a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
24.2% of its profit
Room to growStretchedMore than it earns: 80.8%
News
Corona and Modelo Are Shrinking While Pacifico and Victoria Are Booming. Here's What That Means for Constellation Brands Stock.Yahoo Finance · Oct 7, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
61Pass
Benjamin Graham
38No pass
Philip Fisher
58No pass
Peter Lynch
82Pass
Joel Greenblatt
21No pass
Charlie Munger
60Pass
Terry Smith
50No pass
Questions about Corona Remedies
Is Corona Remedies a good stock to buy?
A solid business, priced as if everything goes right. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Corona Remedies AI analysis
What does Corona Remedies do?
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It is in Drug Manufacturers - General, based in Ahmedabad, India.
Does Corona Remedies pay a dividend?
Yes. At today's price the dividend is 0.3% a year, about 24% of its yearly profit. In 2026 it paid out ₹447 million in dividends.
Is Corona Remedies stock halal?
Yes. Corona Remedies passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Corona Remedies stock done over the past year?
Up 61.5% over the past twelve months, to ₹2,320.60. It traded between ₹1,347.25 and ₹2,540.65 and is 8.7% below its high.
Who are Corona Remedies's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with Corona Remedies's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.